Zobrazeno 1 - 10
of 26
pro vyhledávání: '"R Molero Gómez"'
Publikováno v:
Farmacia Hospitalaria, Vol 38, Iss 2, Pp 123-129 (2014)
Objectives: To assess the quality of Pharmaceutical Interventions of starting a drug treatment based on the available scientific evidence, in an Emergency Department with a Clinical Pharmacist working full-time. To analyze the rate of Pharmaceutical
Externí odkaz:
https://doaj.org/article/9b83e04ba56b41d699540503e761d1cf
Publikováno v:
Farmacia Hospitalaria, Volume: 38, Issue: 2, Pages: 123-129, Published: APR 2014
Farmacia Hospitalaria, Vol 38, Iss 2, Pp 123-129 (2014)
Farmacia Hospitalaria, Vol 38, Iss 2, Pp 123-129 (2014)
Objetivo: Evaluar la calidad de las Intervenciones farmacéuticas que motivaron un Inicio de tratamiento en un Servicio de Urgencias. Analizar el porcentaje de intervenciones sobre tratamientos agudos o crónicos, y el grupo ATC de los fármacos impl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e187f6317086e301d7a592ebb21b05bc
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432014000200008&lng=en&tlng=en
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432014000200008&lng=en&tlng=en
Autor:
RM Damas Fuentes, L Laguna Marmol, MA Padrón Garcia, M Molina Fernandez-Posse, S González-Munguía, MM Díaz Pestano, M Piñero González, L Majuelos Aicart, R Molero Gómez
Publikováno v:
European Journal of Hospital Pharmacy. 22:A142.1-A142
Background Medication systems related to clinical decision support, when implemented in an electronic prescribing program, have the potential to reduce adverse drug reactions. Purpose To increase safety in the prescription and administration of drugs
Autor:
R Molero Gómez, H Alonso Ramos, L Oliva Hernandez, RM Damas Fuentes, MA Padrón Garcia, M Pérez León
Publikováno v:
European Journal of Hospital Pharmacy. 22:A10.1-A10
Background The administration of an intensive dose of statins after acute myocardial infarction (AMI) has proved to be superior to conventional doses in reducing morbidity and mortality (IA evidence) but application in clinical practice is variable.
Autor:
M Pérez León, JJ Ramos Báez, M Amat López, SM Marrero Penichet, R Molero Gómez, S González Munguía, G Herrera Ortega, N Sangil Monroy, V Morales León
Publikováno v:
European Journal of Hospital Pharmacy. 22:A64.2-A64
Background Inappropriate use of antibiotics has become a serious problem in the hospital setting. We implemented a stewardship programme in order to optimise antimicrobial treatment at our hospital. Purpose To analyse the contribution of an antibioti
Autor:
M Pérez León, H Luzardo-Henríquez, R Molero Gómez, M Díaz-Pestano, M Piñero González, S González-Munguía
Publikováno v:
European Journal of Hospital Pharmacy. 22:A6.1-A6
Background Allogeneic hematopoietic stem cell transplantation (HSCT) is the first-line treatment for many haematological diseases. Graft-versus-host disease (GVHD) is the major complication of HSCT. Steroids are the mainstay treatment of GVHD for red
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 28(1)
Primary pulmonary hypertension (PPH) is a disease of un-known etiology that is characterized by an increase in pulmonary arterial pressure. Traditionally its treatment has been based on the administration of the vasodilator therapy with calcium chann
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 27(1)
Plasmatic coagulation has like purpose the formation of a stable clot of fibrina, this process is possible thanks to the intervention of the factors of the coagulation that are plasmatic proteins. Some of these factors are vitamin K dependent (factor
Autor:
M Molina Fernandez-Posse, R Molero Gómez, N Sangil Monroy, RM Damas Fuentes, MM Varela Gonzalez, L Oliva Hernandez
Publikováno v:
European Journal of Hospital Pharmacy. 21:A169.3-A170
Background Bosentan is indicated in the treatment of pulmonary hypertension. Commonly reported adverse reactions are abnormal liver function (10.9%). Purpose To evaluate the risk of hepatotoxicity associated with bosentan, comparing incidence rates w
Autor:
G Herrera Ortega, MM Díaz Pestano, H Alonso Ramos, SM Marrero Penichet, M Amat López, ML Oliva Hernández, R Molero Gómez, M Pérez León, N Sangil Monroy, JJ Ramos Báez, S González Munguía
Publikováno v:
European Journal of Hospital Pharmacy. 21:A166.1-A166
Background Medicines reconciliation studies have produced estimates about rates of patients and drugs involved in unintended discrepancies along the reconciliation process, but to our knowledge no-one has worked out the reasons for these discrepancie